Brief: Orgenesis Selects Therapeutics Inc To Support Planned Study Of Genital Warts Drug
20/08/2020 12:38
Aug 20 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS SELECTS THERAPEUTICS, INC. AS CRO TO SUPPORT
DEVELOPMENT AND PLANNED PHASE 2 CLINICAL STUDY OF RANPIRNASE FOR
THE TREATMENT OF EXTERNAL GENITAL WARTS
* ORGENESIS INC - PARTIES WILL COLLABORATE FOR DEVELOPMENT
OF
ORGENESIS' RANPIRNASE TOPICAL DRUG FORMULATION FOR TREATMENT OF
EXTERNAL GENITAL WARTS
Source text for Eikon: ID:nGNX2RKxy5
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules